Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jiayu Ding

Showing results (31-40 of 44) with videos related to

Pageof 5
Sort By:
Journal of Medicinal Chemistry|January 10, 2025
Discovery of Novel Small-Molecule Inhibitors Disrupting the MTDH-SND1 Protein-Protein InteractionHao Shen, Jiayu Ding, Jiaying Ji, et al.
Physical Review Letters|October 31, 2025
Suppressing Spurious Transitions Using Spectrally Balanced PulseRuixia Wang, Yaqing Feng, Yujia Zhang, et al.
Angewandte Chemie (International Ed. in English)|May 28, 2026
Light-Activated Isolation of High-Quality Mitochondria for Therapeutic TransplantationHui Liu, Yuxin Jiao, Ting Zhang, et al.
Journal of Medicinal Chemistry|July 9, 2025
Design, Synthesis, and Activity Evaluation of Novel Nucleosides as ADAR1 Inhibitor for the Treatment of Prostate CancerYasheng Zhu, Hao Shen, Jiayu Ding, et al.
Journal of Medicinal Chemistry|April 14, 2025
Development of Novel PRMT7 Inhibitors for the Treatment of Prostate CancerJiaxing Li, Chengliang Sun, Ying Zhang, et al.
Journal of Medicinal Chemistry|June 3, 2025
Discovery of a Novel and Potent <i>MET</i> Transcription Inhibitor Targeting Promoter G-Quadruplex for the Treatment of NSCLCWenjian Min, Chunling Chen, Zhongrui Shi, et al.
Journal of Medicinal Chemistry|March 9, 2026
Rational Design of Potent and Orally Efficacious PI3Kα/δ Degrader for PIK3CA Mutant Breast Cancer without Hyperglycemic LiabilityYi Hou, Xinqing Zheng, Yiwen Zhang, et al.
Leukemia|December 20, 2024
ADAR1 is required for acute myeloid leukemia cell survival by modulating post-transcriptional Wnt signaling through impairing miRNA biogenesisZhongrui Shi, Jiaxing Li, Jiayu Ding, et al.
Advanced Science (Weinheim, Baden-Wurttemberg, Germany)|June 20, 2025
ASO Therapy Targeting STAU2 to Inhibit Pancreatic Ductal Adenocarcinoma Progression and Metastasis by Regulating the PALLD-Mediated EMT Signaling PathwayJiayu Ding, Hao Shen, Jiaying Ji, et al.
Nature Communications|May 25, 2022
Targeting dual-specificity tyrosine phosphorylation-regulated kinase 2 with a highly selective inhibitor for the treatment of prostate cancerKai Yuan, Zhaoxing Li, Wenbin Kuang, et al.
Pageof 5

Showing results (31-40 of 44) with videos related to

Sort By:
Pageof 5
Journal of Medicinal Chemistry|January 10, 2025
Discovery of Novel Small-Molecule Inhibitors Disrupting the MTDH-SND1 Protein-Protein InteractionHao Shen, Jiayu Ding, Jiaying Ji, et al.
Physical Review Letters|October 31, 2025
Suppressing Spurious Transitions Using Spectrally Balanced PulseRuixia Wang, Yaqing Feng, Yujia Zhang, et al.
Angewandte Chemie (International Ed. in English)|May 28, 2026
Light-Activated Isolation of High-Quality Mitochondria for Therapeutic TransplantationHui Liu, Yuxin Jiao, Ting Zhang, et al.
Journal of Medicinal Chemistry|July 9, 2025
Design, Synthesis, and Activity Evaluation of Novel Nucleosides as ADAR1 Inhibitor for the Treatment of Prostate CancerYasheng Zhu, Hao Shen, Jiayu Ding, et al.
Journal of Medicinal Chemistry|April 14, 2025
Development of Novel PRMT7 Inhibitors for the Treatment of Prostate CancerJiaxing Li, Chengliang Sun, Ying Zhang, et al.
Journal of Medicinal Chemistry|June 3, 2025
Discovery of a Novel and Potent <i>MET</i> Transcription Inhibitor Targeting Promoter G-Quadruplex for the Treatment of NSCLCWenjian Min, Chunling Chen, Zhongrui Shi, et al.
Journal of Medicinal Chemistry|March 9, 2026
Rational Design of Potent and Orally Efficacious PI3Kα/δ Degrader for PIK3CA Mutant Breast Cancer without Hyperglycemic LiabilityYi Hou, Xinqing Zheng, Yiwen Zhang, et al.
Leukemia|December 20, 2024
ADAR1 is required for acute myeloid leukemia cell survival by modulating post-transcriptional Wnt signaling through impairing miRNA biogenesisZhongrui Shi, Jiaxing Li, Jiayu Ding, et al.
Advanced Science (Weinheim, Baden-Wurttemberg, Germany)|June 20, 2025
ASO Therapy Targeting STAU2 to Inhibit Pancreatic Ductal Adenocarcinoma Progression and Metastasis by Regulating the PALLD-Mediated EMT Signaling PathwayJiayu Ding, Hao Shen, Jiaying Ji, et al.
Nature Communications|May 25, 2022
Targeting dual-specificity tyrosine phosphorylation-regulated kinase 2 with a highly selective inhibitor for the treatment of prostate cancerKai Yuan, Zhaoxing Li, Wenbin Kuang, et al.
Pageof 5